axinn

Axinn Represents Thermo Fisher in \$7.2 Billion Acquisition of Patheon

NEWS | LESS THAN 1 MIN READ

May 17, 2017

Axinn is representing Thermo Fisher Scientific Inc. in its \$7.2 billion acquisition of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The Axinn team consists of John Harkrider and Mark Alexander.

Related People



Mark D. Alexander



John D. Harkrider

Related Services

Antitrust

To subscribe to our publications, click here.

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
 SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
 sponsorship ANTITRUST
- GCR Live: Law Leaders Global 2025
 SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
 EVENT
- SABA North America Corporate Counsel Retreat 2025
 sponsorship ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
 CLIENT ALERTS ANTITRUST
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
 AWARDS & RECOGNITIONS ANTITRUST
- Merger Remedies Back in Vogue Under Trump
 MEDIA MENTIONS ANTITRUST
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation
 AXINN VIEWPOINTS INTELLECTUAL PROPERTY

• A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

@ 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved